HB 2295 is a well-intentioned proposal that aims to improve public health outcomes by adding Duchenne muscular dystrophy (DMD) to Texas’ mandatory newborn screening program. DMD is a severe, progressive muscle-wasting disorder that often goes undiagnosed until a child is several years old—by which point significant and irreversible damage may have occurred. Early detection has the potential to empower families, shorten diagnostic delays, reduce unnecessary testing, and improve access to clinical interventions and supportive services. These benefits are especially important for underserved populations that often face barriers to diagnosis and treatment.
However, while the goal of HB 2295 is laudable, the bill raises important concerns from a limited government and fiscal responsibility perspective. First, it expands the scope of government by requiring the Department of State Health Services (DSHS) to build out new laboratory capacity and hire additional staff to support this new mandate. This is not a marginal adjustment within existing resources—DSHS currently lacks the space and staffing to implement DMD testing and has estimated multi-million-dollar startup costs. These include $710,320 in the first year and $2.9 million in the second year, funded entirely from General Revenue. Although the bill anticipates that Medicaid and private insurance reimbursements will partially offset costs starting in year three, these reimbursements are themselves funded by taxpayers and represent a continued public expenditure.
Second, the bill mandates a medical test for all newborns without offering a clear opt-out or voluntary alternative for parents. This raises questions about parental rights and medical consent, particularly in an area where treatment options, while improving, are still limited. A universal testing mandate—regardless of individual family values, risk factors, or medical circumstances—can be perceived as overreach and inconsistent with principles of informed choice. From the standpoint of individual liberty, expanding access to testing is appropriate, but imposing it by default without a parental decision point may go too far.
Additionally, there are legitimate concerns about whether the benefits of the bill justify the public investment. DMD, while serious, is rare—affecting roughly 1 in 3,500 to 5,000 male births. Lawmakers may reasonably question whether scarce state resources should prioritize costly infrastructure expansions for low-incidence conditions, especially when other public health and early childhood needs remain underfunded.
The bill should be amended to establish an opt-in framework for DMD screening, accompanied by a statewide education initiative targeting healthcare providers and parents. This approach would preserve the goal of early detection while respecting parental choice, minimizing unnecessary government expansion, and allowing families to assess the value of testing within their own medical and ethical frameworks. Furthermore, adding statutory guardrails to future expansions of the newborn screening panel would help ensure that any additions undergo a cost-benefit analysis and receive explicit legislative approval.
In summary, HB 2295 identifies a real public health need and seeks to address it through early intervention. However, it does so in a way that raises valid concerns about government scope, taxpayer burden, and individual choice. These concerns do not require outright rejection of the bill, but they do warrant thoughtful amendments to balance public health goals with liberty, responsibility, and fiscal discipline. Texas Policy Research recommends that lawmakers vote YES; Amend on HB 2295.
Individual Liberty: The bill both enhances and constrains individual liberty. On the positive side, early detection of Duchenne muscular dystrophy (DMD) empowers families with critical medical information, giving them a head start on treatment options, care planning, and access to clinical trials. This enables more informed decision-making and could improve the quality and duration of life for affected children. However, the bill mandates screening for all newborns without a clear opt-out mechanism for parents. This erodes parental autonomy by removing their discretion to accept or decline a test for a rare genetic condition, regardless of their values, beliefs, or perceived risk. From a liberty standpoint, this undermines the principle that individuals—not the state—should control personal healthcare decisions, especially for their children.
Personal Responsibility:
HB 2295 supports personal responsibility by providing early diagnostic tools that enable families to plan ahead. Identifying DMD at birth can give families time to prepare emotionally, medically, and financially, which is consistent with encouraging individuals to take ownership of their circumstances. It also relieves some of the systemic delays that currently shift responsibility to overwhelmed healthcare systems years after symptoms appear. However, this benefit is strongest when families are voluntarily informed and empowered—not compelled—into medical decisions. The bill’s effectiveness in promoting personal responsibility would be enhanced if it relied more on education and voluntary participation than on mandate.Free Enterprise: The bill has minimal direct impact on private businesses, but its implementation relies exclusively on state-run testing infrastructure. It doesn’t incentivize private labs, testing innovation, or competitive service delivery. In effect, it further entrenches a government monopoly on newborn screening services, leaving little room for market alternatives or private sector flexibility. While not imposing new regulatory burdens on businesses, it also doesn’t leverage or expand private enterprise participation. This could be viewed as a missed opportunity to foster innovation or offer families broader options through the private healthcare market.
Private Property Rights: The bill does not affect land ownership, property use, or intellectual property. It does not regulate or seize assets, nor does it impose mandates on how private property is used. Thus, it is neutral with respect to this principle.
Limited Government: HB 2295 increases the size and scope of government. It imposes a new state mandate on all newborns, requires the Department of State Health Services to expand lab capacity and staff, and introduces multi-million-dollar start-up costs that will ultimately be borne by taxpayers—even if some costs are offset by Medicaid or private insurance. From a limited government perspective, this represents mission creep. Even if the underlying intent is compassionate, it reflects a growing trend of state intervention in healthcare, particularly in areas where private solutions, education campaigns, or opt-in models could achieve similar outcomes with less centralization and cost.
